Hyperfine Announces Promising Interim Findings on the Value of ...

united states securities and exchange commission - form 10-k

the interim or final results of the clinical ... The following discussion and analysis of the financial condition and results of operations Hyperfine, Inc.

Two-armed surgical robot prototype targets pediatric brain tumors

Hyperfine announces promising interim findings on portable, ultra-low-field MRI for acute stroke care. Hyperfine has announced the presentation of interim ...

HYPR Achieves Positive Swoop System Data for ECMO - MSN

Hyperfine, Inc. HYPR recently announced a publication by investigators at Johns Hopkins Hospital and the University of Texas-Houston on using the Swoop ...

Hyperfine, Inc.

the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; and. • the FDA concludes that the results ...

Hyperfine Annual Report 2023 Form 10-K (NASDAQ:HYPR) Published

Yes ☐ No ☒. The aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates of the registrant (without ...

Hyperfine Announces Alzheimer's Research with Swoop System Data

Hyperfine Announces Alzheimer's Research with Swoop System Data ... Research supports the value of ultra-low-field MRI in monitoring amyloid- ...

Hyperfine, Inc.

... value $0.0001 per share (“Class A common stock”), held by the sponsor of our ... interim proceedings or developments, and if securities analysts or ...

hyperfine, inc.

... value $0.0001 per share (“Class B common stock”), (iv) 614,000 shares of ... interim proceedings or developments, and if securities analysts or ...

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results · Revenues for the full year 2023 were $11.03 million, up 62%, ...

Hyperfine - Instagram

... Interim data, presented this past weekend, reveals promising advancements in acute #stroke care using the portable Swoop® MR brain imaging system! Key findings ...

Filing - Hyperfine, Inc.

the interim or final results of the clinical trial are inconclusive ... stock or publishes inaccurate or unfavorable research about our business, ...

Form 10-Q for Hyperfine INC filed 05/11/2023

beginning after December 15, 2022, and interim ... research and development credits, and the valuation allowance recorded against the full amount.

Form S-3 for Hyperfine INC filed 11/09/2023

... research or publish inaccurate or unfavorable research about our business, our share price and ... case of unaudited interim statements, to ...

HYPERFINE, INC.

the interim or final results of the clinical trial are inconclusive ... report certain payments and other transfers of value made to U.S.-.

Hyperfine, Inc.

the interim or final results of the clinical trial are inconclusive ... report certain payments and other transfers of value made to U.S.-.